Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02748512 · ClinicalTrials.gov registry record · Phase 3
Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis
A Phase 3 study, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT02748512 is a Phase 3 study that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT02748512, a Phase 3 study, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.
Interventions
- DRUG FAI Insert administered using the Mk II inserter
- DRUG FAI Insert administered using the Mk I inserter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-02-23 |
| Est. Completion | 2017-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02748512
The ClinicalTrials.gov registry entry for NCT02748512 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FAI Insert administered using the Mk II inserter is the first listed.
NCT02748512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02748512 about?
NCT02748512 is a clinical study titled "Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis". This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.
What is the current status of trial NCT02748512?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2016-02-23. Estimated completion is 2017-08-17.
What interventions are being tested in trial NCT02748512?
The interventions under investigation include: FAI Insert administered using the Mk II inserter (DRUG), FAI Insert administered using the Mk I inserter (DRUG).
Who is sponsoring clinical trial NCT02748512?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.